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Available online 21 November 2016Ageing is a leading risk factor for many debilitating diseases. While age-related diseases have been the subject of
over a century of intense investigation, until recently, physiological ageingwas considered unavoidable. Pharma-
cological and genetic studies have since shown that ageing is a malleable process and that its abrogation can pre-
vent its associated diseases. This review summarises a sample of the most promising efforts to deliver the
products of ageing research to the clinic. Current efforts include the use of clinically approved drugs that have
since been repurposed, as well as the development of novel therapeutics, to target ageing. Furthermore, ongoing
research has sought reliable biomarkers of ageing that will accelerate the development of such therapeutics. De-
velopment of these technologies will improve quality of late-life and help relieve the enormous stress placed on
state healthcare systems by a rapidly ageing global population. Thus, for both medical and socioeconomic rea-
sons, it is imperative that ageing is made to yield to intervention.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
The ageing global population represents one of the greatest chal-
lenges to modern society. Ageing is the biggest risk factor for some of
the most debilitating and distressing diseases known, including neuro-
degenerative diseases such as Parkinson's and Alzheimer's, as well asthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Collectively, the diseases of ageing represent the biggest causes of
morbidity and mortality in the developed world (Kennedy and
Pennypacker, 2014). While the study and treatment of these diseases
in isolation has yielded a great deal of knowledge and a signiﬁcant im-
provement in patient quality of life, it is important to acknowledge
that these diseases do not exist in isolation. An aged individualmay pos-
sess any number of co-morbidities, each of which can exponentially
complicate any required therapeutic interventions. Given the
complexity of treating age-related co-morbidities separately, the idea
of targeting ageing itself as a means of reversing the pathogenesis of
several diseases at once is appealing (Faragher et al., 2009).
This review will evaluate current developments in translating basic
ageing research into useful therapeutics. Particular attention will be
paid to ongoing attempts to repurpose already available drugs, before
touching on promising drugs that, based on recent evidence in pre-clin-
ical models, could also be repurposed. Additionally, new therapeutics
being developed speciﬁcally to target ageing are discussed. Finally,
since any appraisal of anti-ageing functionwill only be possible with ro-
bust biomarkers of ageing (Kenessary et al., 2013), we present a brief re-
view of the search for powerful predictors of physiological age. To
highlight strategies with greatest potential to manipulate human age-
ing, only drugs that have demonstrable effects in mammals will be con-
sidered. Other reviews have covered longevity-enhancing treatments in
non-mammalian models (Vaiserman and Marotta, 2016; Vaiserman et
al., 2016).
2. Ageing as a Clinical Indication
Twenty years ago, the eminent epidemiologist Richard Doll argued
that ageing as a single uniﬁed phenomenon did not exist (Peto and
Doll, 1997). Doll proposed that, on the balance of evidence available at
the time, it was better to consider each of the apparently independent
diseases of ageing as separate in nature and thus separate in possible
treatments. Current advances in gerontology have since shown that
many age-related diseases do indeed share common causes and thus
may be reversed or prevented through common cures. Since then the
shift in scientiﬁc consensus from regarding ageing as an inexorable, en-
tropic process to one that is mediated bywell-deﬁned - and important-
ly, malleable - biochemical pathways has been dramatic. Initial studies
in nematodes demonstrated geneticmanipulation of longevitywas pos-
sible (Kenyon et al., 1993). Subsequent studies are just beginning to
tease out the many genetic determinants of human longevity (Zhang
et al., 2016). Brieﬂy, ageing is thought to be caused by developmental
processes that evolved to ensure successful reproductive maturation
but carry on long after reproductive maturity is reached (antagonistic
pleiotropy; Williams, 1957), resulting in molecular and physiological
defects that render organisms frail and less able to respond to stress.
These molecular and physiological defects manifest in many forms
over several hierarchical layers of molecular, cellular and tissue biology.
Cells within old individuals may possess aggregated proteins, dysfunc-
tional mitochondria, (epi)genetic lesions and eroded telomeres. This
can lead to senescence and subsequent depletion of active stem cell
populations, impairing regenerative capacity and further promoting tis-
sue ageing. Systemically, age-related immunodegeneration, disrupted
circadian rhythms, impaired nutrient sensing and improper autocrine
and paracrine signalling processes combine to promote an “aged” extra-
cellular environment, causing or exacerbating organ failure and leading
to the exponential increase in morbidity and mortality that
characterises an ageing population (reviewed by López-Otín et al.,
2013; Kirkwood, 2005; summarised in Fig. 1).
Given that ageing is the biggest risk factor for many debilitating dis-
eases that render individuals frail and rob them of their independence
and dignity, there are strong moral and economic imperatives to tackle
it and prevent the associated pathologies. Newly armed with an idea of
how humans age, numerous companies and government-fundedprogrammes have sprung up to address human ageing as a problem in
and of itself, rather than trying to address the diseases of ageing sepa-
rately. High proﬁle examples include the (formerly Google) Alphabet-
funded ageing research venture, Calico (California Life Sciences Compa-
ny); the interventions testing program (ITP) run by the National Insti-
tute on Aging (NIA), designed to test the longevity-enhancing
potential of a variety of different drugs; and Human Longevity Inc., co-
founded by J. Craig Venter, which aims to elucidate and treat the (epi)-
genetic causes of age-related diseases. Furthermore, the SENS (Strate-
gies for Engineered Negligible Senescence) Research Foundation
performs its own research and helps fund the research of other insti-
tutes, and focuses on utilising combinations of regenerative medicine,
gene therapy and pharmacology to reverse ageing. More recently,
work showing that clearance of senescent cells improves health in old
mice (Baker et al., 2016; and discussed later) prompted the creation of
Unity Biotechnology. Unity is attempting to develop “senolytics” – ther-
apeutics that recapitulate this effect in humans. Meanwhile in Oxford,
UK, Chronos Therapeutics is developing pharmaceuticals to combat
age-related diseases. Far from being an inscrutable, purely academic
problem, both young start-ups and established companies are now see-
ing ageing as a tractable and potentially proﬁtable venture.
3. Repurposing Drugs to Combat Ageing
Finding new applications for existing therapeutics (drug
repurposing) is a commonly used strategy to allow drugs to reach
wider markets and greater numbers of patients (Dudley et al., 2011).
Repurposing drugs that have already made it to themarket is an attrac-
tive strategy formany reasons. Drug development can often cost billions
of dollars (Adams and Brantner, 2006) and take 10–17 years to go from
early phase clinical trials to market-ready product. Drug repurposing
circumvents much of the exploratory work needed to determinemech-
anisms of action, formulation, manufacture procedure and pharmacoki-
netics. Importantly, market-tested drugs have already gone through
clinical trials and have proven their safety and efﬁcacy in their initially
intended application. Consequently, the development time for
repurposed drugs can be markedly reduced (3–12 years).
There are two major approaches of drug repurposing: drug-centred
and disease-centred (reviewed in greater detail by Dudley et al., 2011).
Brieﬂy, drug-centred repurposing relies on the physicochemical proper-
ties (e.g. structural similarity to other drugs) or biological effects (e.g.
similar transcriptome response between different drugs) of the drug
in question. Indirect properties, such as common side-effects between
drugs indicated for different diseases can also be used. More recently,
computational modelling of drug-protein interactions (molecular
docking simulations) can also be used to perform high-throughput
screens of possible interaction partners. Disease-centred approaches
rely on using similarities between different diseases to suggest poten-
tially repurposable drugs. Generally, if two different diseases possess
similar molecular aetiologies, then therapies used to treat one may
also work for the other. The two approaches are not mutually exclusive
and depending on the knowledge available regarding drug and/or dis-
ease of interest, one or both approaches can be utilised.
To facilitate drug-centred repurposing approaches to target ageing,
such as the NIA's ITP, geroprotectors.org provides a database of N250
compounds found to extend lifespan in various model organisms
(Moskalev et al., 2015). Of the 103 compounds listed by geroprotectors.
org that are approved for use in humans, there is already considerable in-
terest in repurposing at least two of them: the immunosuppressant
rapamycin and the anti-diabetic drug, metformin.
3.1. Rapamycin and mTOR Inhibition
Within the gerontology literature, few compounds can claim to have
received as much attention as rapamycin. Rapamycin has been shown
to extend murine lifespan and healthspan (Wilkinson et al., 2012),
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Fig. 1.Mechanisms of human ageing. Ageing affects several systems acting at several hierarchical levels from molecular events such as mitochondrial dysfunction and genomic lesions,
through to cellular events such as senescence or over-proliferation. Dysfunctional cells lead to tissue dysfunction, culminating in organ failure and death. Interactions between levels
serve to exacerbate pathology at all levels. Black lightening symbolises damage or failure; SASP refers to the senescence-associated secretory phenotype.
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binds to FK506 binding protein and serves to inhibit the nutrient-sensi-
tive kinase mTOR (mechanistic target of rapamycin) complex I
(mTORC1) (Banaszynski et al., 2005). Inhibition of mTORC1 leads to
pleiotropic effects that are thought to improve protein andorganelle ho-
meostasis by relieving inhibition of autophagy and proteasome function
while simultaneously suppressing protein translation (Hill et al., 2010;
Yu et al., 2010). mTOR also regulates mitochondrial biogenesis and
lipid homeostasis through PPARγ and PGC1α (Fig. 2; reviewed by
Laplante & Sabatini, 2009). Rapamycin treatment has been shown to re-
verse amyloid-β aggregation and improve brain vascularisation in
Alzheimer's disease mouse models, as well as cognitive function in
these disease models and wild-type mice (reviewed by Richardson et
al., 2015). Rapamycin also prevented neuronal cell death in toxin-
induced models of Parkinson's disease (Malagelada et al., 2010).
Rapamycin is currently approved for clinical use as an immunosuppres-
sant following organ transplantation. Surprisingly however, RAD001, a
rapamycin analogue, was shown to improve inﬂuenza vaccination re-
sponse in elderly patients (Mannick et al., 2014). Mannick et al. suggest
that RAD001 may suppress chronic inﬂammatory phenotypes rather
than general immune function, presumably by bringing mTORC1 activ-
ity back to levels observed in young individuals, although this remains
to be tested. Furthermore, it is difﬁcult to assess the relevance of any ob-
served increase in vaccination response without comparison to young
controls. Importantly, while rapamycin has been shown to extend
lifespan in a variety of pre-clinical models, the precise effects in micehave been shown to be sex-speciﬁc (Garratt et al., 2016; Miller et al.,
2014) and speciﬁc to particular genetic backgrounds (Lamming et al.,
2013, 2012). Notably, rapamycin was shown to increasemortality in di-
abetic mice (Sataranatarajan et al., 2016). Furthermore, a genetically
heterogeneous mouse line fed high doses of rapamycin showed in-
creased incidence of cataracts and testicular atrophy (Wilkinson et al.,
2012). These studies highlight the need for greater personalisation in
medicine to distinguish those that might most beneﬁt from any give
treatment. To address apparent genetic and environmental effects on
rapamycin-mediated longevity extension, the Dog Aging Project (DAP;
dogagingproject.com), led by researchers at the University of Washing-
ton, is currently trailing rapamycin on domesticated dogs. The logic be-
hind DAP being that domesticated dogs possess high genetic variability
due to decades of selective breeding and share the variability of envi-
ronmental conditions possessed by their human owners. A signiﬁcant
positive effect on canine longevity and healthspan would mean that
rapamycinwas able to overcome any genetic or environmental variabil-
ity and bodes well for potential trials on human populations.
3.2. TAMEing Ageing With Metformin
Metformin is an anti-diabetic drug that is thought to activate adeno-
sinemonophosphate-activated kinase (AMPK) tomodulate glucose ho-
meostasis (Shaw et al., 2005). However, other reports suggest that
metformin possesses pleiotropic activity (Foretz et al., 2010) and can
modulate a variety of downstream processes related to ageing (Fig. 2).
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Fig. 2.Mechanisms of promising repurposed anti-ageing drugs. Metformin and rapamycin are thought to act synergistically to improve protein and energy homeostasis. Inhibitors of IL-6
andNF-κB could act to reverse systemic inﬂammation and TFGβ inhibitors have been shown to reverse aberrant signalling causedby an aged stemcell niche (ofwhich extracellularmatrix
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effect when administered early in life, possibly independent of
metformin's glucose-lowering effect (Anisimov et al., 2011). To capital-
ise on these results, metformin is now the subject of a ﬁrst-of-its-kind
clinical trial (funded by the American Federation of Aging Research) to
see if it does indeed prevent ageing. The TAME (Targeting Ageing with
Metformin) study is designed to test if metformin possesses longevi-
ty-enhancing properties independent of its anti-diabetic effects. Fur-
thermore, the TAME study aims to establish a benchmark in clinical
trial designwhich can be applied to test other compoundswith putative
anti-ageing effects (Barzilai et al., 2016). Measuring rates of ageing in
human cohorts poses an interesting methodological problem. The gold
standard for measuring rates of ageing in model organisms is to mea-
sure lifespans via construction of Kaplan-Meier survival curves and per-
form subsequent Gompertz analysis (Gompertz, 1825). However, this
method cannot be applied to clinical trials involving human subjects
on a reasonable time-scale. The TAME study aims to use time before ap-
pearance of next co-morbidity as a proxy for rate of ageing. Health de-
clines exponentially with time in ageing populations, leading to the
sudden drop in survival - caused by increasingly rapid appearance of
co-morbidities over time - observed in survival curves assembled from
ageing populations. However, this approach still requires a signiﬁcant
amount of time and it remains to be seen if biomarker-based ap-
proaches (discussed later) can prove quicker or more efﬁcient.3.3. Second Generation Repurposed Anti-ageing Compounds?
If successful, rapamycin and metformin could represent the ﬁrst
generation of therapeutics speciﬁcally indicated for use against ageing.
Once ageing is deﬁned as something that is treatable, other drugs that
have been shown to act on some relevant ageing target could be similar-
ly repurposed, with the knowledge gained from rapamycin andmetfor-
min informing their trial and marketing strategies. For instance, given
the systemic implications of age-related immunodegeneration and
chronic inﬂammation in ageing systems, drugs that act on the immune
system show considerable promise in manipulating age-related disease
pathogenesis.
Interleukin-6 (IL-6) is secreted by senescent cells and is thought to
promote pleiotropic effects alongwith the chronic, sterile inﬂammation
that characterises tissue ageing. Signalling through IL-6 receptor has
been shown to increasewith age and been associatedwith an increased
risk of coronary heart disease (Bujak and Frangogiannis, 2007; Sarwar
and Butterworth, 2012). Recently, tocilizumab, an antibody-based ther-
apeutic that targets the IL-6 receptor to block receptor-ligand interac-
tions passed clinical trials. Tocilizumab is currently used to treat
severe rheumatoid and juvenile arthritis, but drugs like tocilizumab
could show considerable promise in preventing cardiac ageing. Howev-
er, it should be noted that tocilizumab is associatedwith several side-ef-
fects, such as increased urinary tract infections and ﬂu-like symptoms,
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current indications.
Nuclear factor κB (NF-κB) is a pro-inﬂammatory transcription factor
that is upregulated with age and is also thought to promote the age-re-
lated increase in systemic inﬂammation (Adler et al., 2007). Inhibition
of NF-κB has previously been shown to reverse cardiac hypertrophy (a
common age-related complication) by modulating extracellular matrix
(ECM) composition (Kumar et al., 2011). Notably, knockout of inhibito-
ry NF-κB subunits in mice resulted in a progeroid phenotype that could
be inhibited with anti-inﬂammatory drugs (Jurk et al., 2014). Many NF-
κB inhibitors exist that act at several levels of the canonical or non-ca-
nonical NF-κB pathways with varying degrees of speciﬁcity (Gilmore
and Herscovitch, 2006). Aspirin has been shown to non-speciﬁcally in-
hibit NF-κB (Kopp and Ghosh, 1994), as has metformin, possibly con-
tributing to its apparent anti-ageing effects (Moiseeva et al., 2013).
Several other drugs that inhibit NF-κB are currently approved for clinical
use, though aswith aspirin andmetformin, they are thought to act indi-
rectly (Miller et al., 2010). Drugs that directly inhibit NF-κB, such as PBS-
1086 (Fabre et al., 2012) and IT-901 (Shono et al., 2016) have shown
promising pre-clinical results in cancer studies but have not yet been
approved for clinical use.
Aside from manipulating the immune system, recent studies using
heterochronic parabiosis (surgical connection of the circulatory systems
of two mice of different ages) has implicated several members of the
transforming growth factor β (TGFβ) family in age-related disease
(reviewed by Conboy et al., 2015). TGFβ family members are involved
in regulation of a variety of developmental and regenerative processes
inmany tissues. TGFβ is primarily thought to regulate stem cell function
through altering niche composition by promotion of ECM synthesis and
secretion (Fisher et al., 2016; Trappmann et al., 2012). ECM composition
has been shown to change with age in many tissues and can dictate
stem cell regenerative capacity (Sun et al., 2011). Pharmacological inhi-
bition of TGFβ signalling using 2-(3-(6-Methylpyridin- 2-yl)-1H-
pyrazol-4-yl)-1,5-naphthyridine to inhibit the kinase activity of TGFβ
receptor type-I (TGFBR1) reversed the deleterious effects of ageing on
neurogenesis and skeletal muscle mass (Yousef et al., 2015). Several
TFGβ inhibitors are currently undergoing clinical trials to test their safe-
ty and efﬁcacy on various types of cancers (see tables 1 and 2 in Buijs et
al. 2012). Among these compounds is LY2157299, a TGFBR1 inhibitor
currently involved in phase II clinical trials against pancreatic, liver
and central nervous system cancers. If approved, LY2157299 may also
be a promising drug to repurpose against other, age-related diseases.
4. New Compounds Speciﬁcally Developed to Target Ageing
While repurposing existing therapeutics is a pragmatic, commercial-
ly sound strategy, there are numerous potential anti-ageing targets that
remain to be exploited. Examples include:
4.1. NAD+ Supplementation
Mitochondrial dysfunction and broad metabolic perturbation are
considered hallmarks of ageing (López-Otín et al., 2013). Gomes et al.
(2013) showed that nicotinamide adenine dinucleotide (NAD+) levels
in the nucleus decreasedwith age in skeletal muscle, resulting in imbal-
ance between nuclear andmitochondrial gene expression (Fig. 3A). Fur-
thermore, Gomes et al. went on to show that restoration of NAD+ levels
could reverse many of the biochemical features of skeletal muscle age-
ing. While NAD+ itself is poorly absorbed, nicotinamide mononucleo-
tide (NMN) feeding has been show to increase circulating NAD+
levels in mice eating supplemented food, leading to the prospect of
NMN and another precursor, nicotinamide riboside (NR; currently
available as a supplement) being marketed as anti-ageing drugs. How-
ever, while several biochemical features associated with muscle ageing
were reversed by NMN feeding, it is unknown if this resulted in im-
proved muscle function or healthspan. Furthermore, these studieshave only been conducted on mice and the effects of NMN/NR/NAD+
supplementation on humans are largely untested. Additionally, NR is
also found in trace amounts in milk, questioning how necessary expen-
sive supplementation is compared to cheaper dietary adjustments.
4.2. Senolytics
Recently, Baker and colleagues have shown that ablation of senes-
cent cells in old mice can extend longevity and reverse age-related
decline of function in heart and kidney (Baker et al. 2016). Senescent
cells accumulate in aged tissues due to DNA damage, oncogene activa-
tion, telomere erosion and mitochondrial dysfunction (Moiseeva et al.,
2009; Wiley et al., 2015). Senescence of stem cell populations results
in a decrease in number of stem cells able to contribute to tissue regen-
eration following injury or illness. Furthermore, senescent cells secrete
speciﬁc growth factors, cytokines (such as IL-8 and IL-6) and matrix re-
modelling factors. These factors, collectively known as the senescence-
associated secreted proteome (SASP) serve to remodel the surrounding
environment to prevent migration and proliferation of surrounding
cells. This serves two purposes: 1) to prevent cancer, and 2) to recruit
macrophages to clear the senescent cells. However, due to a combina-
tion of immunodegeneration and aberrant inter-cellular signalling dur-
ing ageing, senescent cells become death-resistant and can persist in
their host tissues. Treatment with the small molecule, ABT-737 has
been shown to selectively kill senescent cells in vivo by inhibition of
the speciﬁc anti-apoptotic proteins which they depend on for survival
(Yosef et al., 2016). Clearance of senescent cells may prevent further
SASP-mediated remodelling (Fig. 3B) and allow matrix deposition and
remodelling that increases regenerative capability (Calhoun et al.,
2015). However, senescent cells are also thought to play important
roles in wound healing and regeneration. For example, SASP-mediated
leukocyte inﬁltration has been shown to mediate the potent regenera-
tive capabilities possessed by certain salamander species (Yun et al.,
2015). Furthermore, senescence of pancreatic β-cells has been shown
to increase insulin secretion and improve glucose homeostasis in a
mousemodel of diabetes (Helman et al., 2016). A ﬁner, potentially com-
plementary approachmay be tomanipulate the SASP itself to eliminate
long-term detrimental effects, such as chronic inﬂammation and im-
paired regeneration, while maintaining short-term beneﬁcial effects
(e.g. cancer prevention and wound healing; reviewed by Malaquin et
al. 2016).
5. Biomarkers for Detecting Drug Efﬁcacy Against Ageing
To accurately assess the impact of possible therapeutics on human
ageing, suitable biomarkers that correlate with, and are likely causative
of, increased physiological age are needed. A biomarker for ageing can
be conservatively deﬁned as “a biological parameter of an organism
that either alone or in somemultivariate composite will, in the absence
of disease, better predict functional capacity at some late age than will
chronological age” (Baker and Sprott, 1988; Martin-Ruiz and von
Zglinicki, 2014). Ideal biomarkers must also be simple and uninvasive
to assess (i.e. not causing lethality inmodel organisms or signiﬁcant dis-
comfort in humans). Molecular biomarkers of physiological age have
historically been controversial; often showing little predictive power
of subsequent morbidity or mortality. Notably, variation in sampling
methods for the same parameter can make comparison difﬁcult
(Cooper et al., 2011). Proposed molecular biomarkers of ageing also
tend to be speciﬁc to ageing in certain cell-types and not representative
of the physiological age of the organism as a whole. Notably, in humans,
a meta-analysis by Chen et al. (2016) has shown that age-related
changes in methylation pattern in different sets of CpG dinucleotides
strongly correlate with all-cause mortality across a variety of ethnic
groups.
Controversially, telomere length has also been proposed as a bio-
marker for ageing (Der et al., 2012). Telomeres are structural caps that
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Fig. 3. Promising novel drugs designed to target ageing. (A) NAD+ supplementation seeks to improve nuclear-mitochondrial communication in old cells and avoid accumulation of
orphaned, hydrophobic electron transport chain subunits, thus aiding protein and organelle homeostasis. (B) Senolytic drugs act to remove senescent cells from tissues and thus ablate
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gradual erosion following successive replication cycles. Telomeres also
prevent chromosome ends from being recognised by DNA repair ma-
chinery as double-strand breaks and “repaired”, which would lead to
aneuploidy. However, recent studies have shown that telomere length
is no better a predictor of age-related morbidity than chronological
age (Glei et al., 2016). Telomere length is typically measured in leuko-
cytes isolated from blood samples. Given that these cells are terminally
differentiated and unlikely to divide again, their telomere length may
not be indicative of regenerative capacity or ability to respond to stress.
Nevertheless, telomere extending drugs are in development (Harley et
al., 2011) and have received notable attention in the popular press
(Kendrick, 2009). One such drug, TA-65, like NMNmentioned previous-
ly, is currently marketed as a supplement, rather than medicine, mean-
ing that Geron - TA-65′s parent company - does not have to seek
approval from the Food and Drug Administration (FDA) to sell it in the
USA. It remains to be seen if this is a viable long-term strategy for a com-
pound that purports to have a medically relevant impact on an integral
aspect of cell biology.
Discerning which of the myriad of changes that occur with age are
the most powerful predictors of morbidity or mortality may require
processing large and complex datasets, potentially incorporating
searches of genomic, transcriptomic and proteomic depositories. The
continued development of new computational and machine learning
methodologies will be required to countenance all the variables at
play. Zhavoronkov and colleagues used neural networks trained on
60,000 patient blood samples and information obtained from routine
health checks (Putin et al., 2016). They found that the ensemble of neu-
ral networks that performed best in predicting age-related outcomes
were those that relied on a large combination of biomarkers to maketheir prediction. This result suggests that, given the complexity of age-
ing, it is likely that no single biomarker will have the greatest predictive
power under all circumstances.6. Conclusions
Ultimately, themost promising therapeutics for targeting ageing ap-
pear to be those that produce systemic effects at several hierarchical
levels. For example, manipulation of autophagy, the unfolded protein
response and mitochondrial function with rapamycin has systemic ef-
fects on cell physiology, but also has been shown tomarkedly affect im-
mune function with systemic consequences for the whole organism.
Furthermore, ablation of senescent cells is thought to be beneﬁcial due
to abrogation of the SASP and its detrimental downstream signalling ef-
fects that can propagate senescence through a tissue and possibly be-
yond. The nature of the currently most promising therapeutics
highlights a fundamental aspect of human ageing – that there is likely
no singular cause and that many separate causes must be addressed si-
multaneously to observe signiﬁcant gains in maximum healthspan. Al-
though some causes are easier to address than others, the commercial
applicability of much of ageing research is still a long way off. Study de-
signwill play amajor role and is a subject of intense scrutiny (discussed
further by Justice et al. (2016)). Furthermore, accuracy of current ageing
biomarkers is still poor and will continue to hamper therapeutic efforts
until addressed. Importantly, current efforts to identify ageing bio-
markers typically try to ﬁnd correlations with mortality. Few attempts
have beenmade (seeMartin-Ruiz et al., 2011) to correlate themwith in-
dicators of frailty or multi-morbidity which might enhance their prog-
nostic potential.
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The therapeutics mentioned in this review are a small sample of
some of the most promising clinical pharmacological approaches to
tackling age-related diseases. Assessing the potential systemic anti-age-
ing effects of therapeutics currently used to treat speciﬁc age-related
diseases could provide additional repurposable drugs. However, any
possible translational beneﬁts will be contingent on greater enrolment
of the elderly in clinical trials. Elderly individuals (65 or older) are typ-
ically under-represented in clinical trials. This is understandable to an
extent; age represents a signiﬁcant source of variability between indi-
viduals (i.e. different people age differently), even in identical twins
(Brodin et al., 2015), and the presence of different co-morbidities be-
tween elderly individuals is a major confounding variable that can ex-
ponentially complicate the interpretation of trial data. The exorbitant
cost of clinical trials means that companies will try to limit variability
to increase the likelihood of correctly discerning statistically signiﬁcant
effects. Unfortunately for those involved however, this variability and
resulting expense must be endured if anti-ageing therapeutics are to
be trialled properly. Devising novel strategies that mitigate costs to
allow greater enrolment of elderly individuals will be a considerable
challenge in a nascent anti-ageing biotech industry.
In regards to research, other nascent strategies, such as stimulating
IL-33 signalling to provoke clearance of amyloid-β plaques and restora-
tion of synaptic plasticity in Alzheimer's disease (Fu et al., 2016), will
continue to excite the gerontology research community and hammer
home the notion that physiological ageing is not an inexorable process.
Instead, like any other pathology, ageing is something tangible that can
be addressed by modern medicine. Successful application of these new
strategies in the clinic will signiﬁcantly reduce the economic burden of
our rapidly ageing population and improve both quality and quantity of
life.
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